Wenwu Liu

6PUBLICATIONS
10CO-AUTHORS
Molecular targetsMedical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Organic chemical synthesis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 04, 2026
Structure-Based Drug Design to Identify Potent, Selective, and Orally Available Cyclin-Dependent Kinase 9 Inhibitors for the Treatment of Castration-Resistant Prostate Cancer.

|Mar 12, 2026
Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer.

Yaoguang Huang, Wenwu Liu, Xiaoyu Shi

|Mar 06, 2026
Novel β-Carboline Derivative ZLWH-67 Exerts Potent Anti-MRSA Activity through Multiple Mechanisms.

Jiacheng Zhuang, Junjie Lin, Wenjie Liu

|Dec 18, 2025
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability.

Yaoguang Huang, Lianyu Tang, Xiaoyu Shi

|Nov 15, 2025
Fluorocyclopropyl-Containing Tacrine Derivatives as Potent and Selective Dual CDK2/CDK9 Inhibitors for the Treatment of Colorectal Cancer.

Limeng Wu, Wenjie Liu, Xinyue Ning

|Sep 20, 2025
Catalyst-Controlled Switchable Mono-/Di-C-H Arylation of Aromatic Amides with Arylsilanes.

Menglong Lu, Deyu Wu, Tingting Hou

Pageof 1

Frequent Collaborators

3 joint publications

Qingchun Zhao

2 joint publications

Yi Dong

2 joint publications

Jingming Jia

1 joint publications

Heng Xu